Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 4,139 Shares of Stock

January 29, 2026 by InsiderTrades.com

Key Points

Major shareholder Chidozie Ugwumba has been selling heavily in mid–late January, disposing of roughly 128,258 shares across multiple trades (most recently 4,139 on Jan. 27), trimming his position to 589,046 shares valued at about $2.99M (a ~0.70% reduction).
Clene trades near $4.91 with 50‑ and 200‑day moving averages of $6.54, a market cap of roughly $53.3M, negative EPS and a one‑year range of $2.28–$13.50, reflecting weak near‑term fundamentals.
Analyst coverage is mixed but leans positive (six Buys, one Sell) with a MarketBeat consensus of "Moderate Buy" and a $32.60 target, while elevated short interest (~752,820 shares, ~10.7% of float) could increase volatility.

Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 4,139 shares of the stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $5.08, for a total value of $21,026.12. Following the sale, the insider owned 589,046 shares of the company's stock, valued at approximately $2,992,353.68. This represents a 0.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total value of $42,800.47.
On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total value of $32,218.36.
On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total value of $29,280.12.
On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total value of $67,377.80.
On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total transaction of $61,200.95.
On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60.
On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The stock was sold at an average price of $5.13, for a total transaction of $40,644.99.
On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total transaction of $64,071.30.
On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The stock was sold at an average price of $5.12, for a total transaction of $100,459.52.
On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The shares were sold at an average price of $4.89, for a total transaction of $127,653.45.

Clene Price Performance

NASDAQ CLNN opened at $4.91 on Thursday. The stock's fifty day moving average price is $6.54 and its 200 day moving average price is $6.54. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The company has a market cap of $53.27 million, a price-to-earnings ratio of -1.45 and a beta of 0.87.

Clene (NASDAQ:CLNN - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Research analysts expect that Clene Inc. will post -5.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on CLNN. Benchmark restated a "buy" rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reissued a "buy" rating on shares of Clene in a report on Wednesday, December 3rd. D. Boral Capital reaffirmed a "buy" rating and issued a $23.00 price target on shares of Clene in a report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Clene in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.60.

Read Our Latest Stock Analysis on Clene

Institutional Trading of Clene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp purchased a new position in Clene in the third quarter valued at $29,000. Jane Street Group LLC acquired a new stake in shares of Clene during the 2nd quarter valued at about $47,000. Lunt Capital Management Inc. increased its stake in shares of Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock valued at $199,000 after purchasing an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP raised its holdings in Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company's stock worth $558,000 after purchasing an additional 42,750 shares during the period. Institutional investors and hedge funds own 23.28% of the company's stock.

Key Stories Impacting Clene

Here are the key news stories impacting Clene this week:

Positive Sentiment: Analysts give a fresh consensus "Moderate Buy" rating, which could support the stock if sentiment or fundamentals improve. Article Title
Neutral Sentiment: There are conflicting short‑interest reports in late January showing "0 shares" on some dates (likely data errors). This creates short‑interest data uncertainty for traders relying on up‑to‑date borrow/cover signals.
Negative Sentiment: Major shareholder Chidozie Ugwumba sold a total of ~19,274 CLNN shares across Jan. 26–28 (sales of 6,418 @ $5.02, 4,139 @ $5.08 and 8,717 @ $4.91), netting roughly $96k and reducing his stake. Insider selling of this size from a >10% holder often signals near‑term selling pressure. SEC filing: SEC Filing
Negative Sentiment: Short interest jumped earlier in January — as of Jan. 15 there were 752,820 shares short (up 45.7% from Dec. 31), representing ~10.7% of the float and a ~5.5 days‑to‑cover. Elevated short interest can accelerate downward moves and increase volatility if negative catalysts persist.

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).